Ultragenyx Pharmaceutical Inc.
RARE
$34.72
-$0.68-1.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.49% | -8.28% | 16.37% | 17.66% | -4.09% |
| Total Depreciation and Amortization | 1.64% | 10.48% | 21.78% | 65.30% | 68.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.86% | 24.14% | -15.25% | -5.56% | -32.57% |
| Change in Net Operating Assets | -1.10% | 71.01% | 1,001.00% | 128.50% | -46.02% |
| Cash from Operations | 12.72% | 5.25% | 43.16% | 33.74% | -21.59% |
| Capital Expenditure | 58.77% | 59.13% | 56.24% | 85.59% | 87.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.14% | 198.08% | -502.83% | -44.80% | -28.38% |
| Cash from Investing | 26.96% | 196.00% | -528.50% | -39.08% | -15.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -99.04% | -83.46% | 1,090.62% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -91.64% | 91.97% |
| Cash from Financing | 370.69% | -99.04% | -55.72% | 1,065.78% | 91.97% |
| Foreign Exchange rate Adjustments | 313.25% | -324.21% | 278.07% | -376.47% | -421.80% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 53.64% | -82.99% | -1,035.71% | 2,179.24% | -110.59% |